Asuragen Inc (Asuragen), a subsidiary of Bio-Techne Corp, is an oncology molecular diagnostic company that offers laboratory medicine solutions. The company's products include amplidex, quantidex and custom reagents among others. It provides custom and companion diagnostic services that include commercialization, product approval, development, discovery, partnered research and development and tumor bank programs. Asuragen’s custom reagents comprise armored reagents in vitro transcribed RNA and plasmid DNA kits. The company distributes its products across Algeria, Australia, Austria, Belgium, Brazil, Bulgaria, Denmark, Egypt, Germany, Iceland, India, the UAE, the UK and the US. Asuragen is headquartered in Austin, Texas, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Asuragen Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Asuragen Inc Company Overview
Asuragen Inc Company Snapshot
Asuragen Inc Pipeline Products and Ongoing Clinical Trials Overview
Asuragen Inc – Pipeline Analysis Overview
Asuragen Inc - Key Facts
Asuragen Inc - Major Products and Services
Asuragen Inc Pipeline Products by Development Stage
Asuragen Inc Pipeline Products Overview
AmplideX SMA Plus Kit - Spinal Muscular Atrophy
AmplideX SMA Plus Kit - Spinal Muscular Atrophy Product Overview
Companion Diagnostic Test - Huntington's Disease
Companion Diagnostic Test - Huntington's Disease Product Overview
Immunomagnetic Micro-Aperture Chip System
Immunomagnetic Micro-Aperture Chip System Product Overview
miRNA Based Sequencing Test - Colon Cancer
miRNA Based Sequencing Test - Colon Cancer Product Overview
miRNA Based Sequencing Test - Esophageal Cancer
miRNA Based Sequencing Test - Esophageal Cancer Product Overview
miRNA Based Sequencing Test - Lung Cancer
miRNA Based Sequencing Test - Lung Cancer Product Overview
miRNA Based Sequencing Test - Pancreatic Cancer
miRNA Based Sequencing Test - Pancreatic Cancer Product Overview
Signature CF Expand
Signature CF Expand Product Overview
Asuragen Inc - Key Competitors
Asuragen Inc - Key Employees
Asuragen Inc - Locations And Subsidiaries
Head Office
Recent Developments
Asuragen Inc, Recent Developments
Oct 31, 2022: Asuragen to Showcase Innovative Diagnostic Lab Solutions at AMP 2022 Conference
Nov 08, 2021: Asuragen launches new kit to enable broader coverage of gene variants linked to cystic fibrosis
May 10, 2021: Multisite study demonstrates utility of Asuragen kit for identifying variants linked to spinal muscular atrophy
Nov 10, 2020: Asuragen to present at Association for Molecular Pathology (AMP) 2020 Annual Meeting
Jul 07, 2020: Asuragen announces CE Mark of AmplideX SMA Plus Kit
Jun 02, 2020: Asuragen to present at 2020 European Society of Human Genetics (ESHG) Virtual Conference
Mar 16, 2020: Asuragen develops RNA Quant technology for coronavirus assays
Feb 24, 2020: FDA grants marketing authorisation for Fragile X Syndrome test
Nov 26, 2019: Asuragen and Wave Life Sciences to create diagnostics for Huntington's
Nov 06, 2019: Asuragen announces launch of AmplideX PCR/CE SMN1/2 Plus Kit